Abstract Body

Background

Chimeric antigen receptor (CAR) T cell therapy represents a promising strategy for achieving HIV remission. We previously described Hybrid CAR-T cells engineered to secrete broadly neutralizing antibodies (bNAbs), which mediate both direct killing and Fc-dependent functions. Here, we present extended validation across additional donors, antigen-specific activation, resistance to infection and new in vivo studies relevant to tissue reservoir targeting.

Methods

Functional assays were performed across multiple donors to assess cytotoxicity, bNAb secretion, HIV neutralization and initiation of Fc-mediated functions. Hybrid CAR-T cells were assessed for antigen-specific activation responses evaluating CD69 expression and expansion kinetics following exposure to HIV+ targets. Additionally, CAR-T cell resistance to HIV infection was investigated. In vivo therapeutic efficacy was assessed in humanized mouse models, with quantitative analysis of HIV DNA levels across multiple tissue compartments.

Results

Hybrid CAR-T cells demonstrated antigen-specific activation, with CD69 upregulation upon HIV antigen encounter, translating into enhanced expansion responses. Importantly, Hybrid CAR-T cells maintained resistance to HIV infection while preserving therapeutic function. In vivo studies revealed substantial HIV DNA reduction in spleen, lung and bone marrow, indicating reservoir targeting across diverse anatomical sites (Figure 1).

 

 

Conclusions

Hybrid CAR-T cells secreting bNAbs not only exert cytotoxic and antibody-mediated functions but also display activation, antigen-specific expansion, viral protection and multi-tissue therapeutic efficacy in vivo. These findings underscore the translational potential of this dual-function CAR platform as a candidate for HIV remission strategies. 

Table or Figure